Margin trajectory and valuations to limit upsides
Third private sector company to report quarterly revenue of Rs 50,000 crore
Adani Enterprises on Wednesday reported 282.2 per cent rise in consolidated net profit at Rs 233.95 crore for the quarter ended March 31, 2021.
The stock surpassed its previous high of Rs 1,121.85 touched on September 2020 and was trading at the highest level since July 2017
Nomura has one of the most conservative estimates with standalone net profit seen at Rs 794 crore, up around 28 per cent YoY
Alembic Pharma Q4FY21 operational performance was marginally below estimates, largely due to lower traction in US and Domestic Formulation (DF) sales
Its profit after tax for the reporting quarter stood at Rs 75 crore against Rs 114 crore in the year-ago period
Net sales rise 6% to Rs 1,280 cr; API business expands by as much as 38%
RBL is a small-sized private lender
Total expenses declined to Rs 2,526.91 crore against Rs 3,099.18 crore.
The stock has corrected 27 per cent from its all-time high level of Rs 9,952 touched on February 5
Drug firm Morepen Laboratories on Tuesday reported an over two-fold rise in its consolidated net profit at Rs 26.76 crore for the quarter ended March 31, 2021, on account of higher revenue
The management said during the quarter, the company's profits was muted due to one off in US operations caused by Polar Vortex leading to sharp rise in gas prices.
The net NPAs improved to 1.97% as on March 2021 from 4.19% in March 2020. NNPA stood at 2.75% (on proforma basis) in Dec 2020.
While Mukesh Ambani-led RIL posted a 108 per cent year-on-year (YoY) rise in profit after tax for the fourth quarter of FY21 at Rs 13,227 crore, it fell short of Bloomberg estimates of Rs 13,704 crore
Total income in January-March 2021 jumped multi-fold to Rs 20,897 crore
Laurus is well poised to follow the success story of some leading CDMO players backed by strong chemistry and integrated model
The private sector lender's standalone net loss widened marginally to Rs 3,788 crore in the March quarter of FY21 as against a net loss of Rs 3,668 crore a year ago
Analysts expect ramp-up in biosimilars to be gradual
On a weekly basis, both the frontline indices snapped their 3-week losing streak and added around 2 per cent higher each